The ODYSSEY Outcomes trial: Clinical implications and exploration of the limits of what can be achieved through lipid lowering


  • Proprotein convertase subtilisin/kexin type 9 inhibitors reduce risk for major adverse cardiac events.
  • There is debate about efficacy in patients with low-density lipoprotein cholesterol <100 mg/dL.
  • Longer trials are needed to adequately address this question.


J Clin Lipidol. 2018 Sep - Oct;12(5):1102-1105. doi: 10.1016/j.jacl.2018.05.016. Epub 2018 Jun 1


Maki KC


Copyright ┬ę 2020 | SICS S.r.l. - Via Boncompagni 16 - 00187 Roma | Partita IVA: 07639150965
Con il contributo educazionale DIETOSYSTEM